The Most Profitable Phase for Biotech Stocks 🧪

Phase 2 is often the most profitable time to be involved in a small cap biotech stock. Here's why. [Liberty Through Wealth]( SPONSORED [WANTED: People Who HATE Flipping Houses... but LOVE Collecting Real Estate Income]( [Angry Business Woman]( It seems EVERYONE wants to get rich from real estate... Until they realize how much @#$% work it is! But there's a better way. In fact, Forbes says this special type of real estate investment has "a long history of outperforming direct real estate investing." And it takes just five minutes to get started. [Click here to see how you can make "flipless" real estate money.]( Wednesday Wealth Recap - With vaccinations on the rise, the talking heads in the media are starting to praise the government for getting COVID-19 under control. But Alexander Green points out that [two other entities - not government - deserve the kudos](. - No one likes being second best. But, as Nicholas Vardy explains, there are actually [some major benefits]( that come with being a second mover in a market. - If you're into fast-paced, exciting trades and being part of a lively community, The War Room might be for you. Our colleagues Karim Rahemtulla and Bryan Bottarelli are hosting a free "open house" for their War Room trading research service April 12-16. They'll be providing premarket commentary, free training, live trade recommendations and more. [Click here to learn more.]( Note from Managing Editor Allison Brickell: Today we'll be hearing from Marc Lichtenfeld, the dividend and biotech investing expert at our sister e-letter Wealthy Retirement. Marc once delivered a rare and stunning 2,381% gain in 10 months in his Lightning Trend Trader research service - a personal record. (This was a partial closeout. The average gain ended up at 907%.) And he's excited to try to beat that record with a brand-new recommendation. Plus, he's willing to offer a free year of his service to new subscribers. To learn why Marc is giving away such valuable research for free - and how you can learn about his latest pick - [click here](. THE SHORTEST WAY TO A RICH LIFE A Powerful Buy Signal Marc Lichtenfeld | Chief Income Strategist | The Oxford Club [Marc Lichtenfeld] Not long ago, I received a call from an investor relations representative who wanted to know whether I'd be interested in hearing about a small biotech company with a drug candidate in Phase 2 trials. Do Yankees fans want Aaron Judge back in the lineup? Phase 2 trials are my favorite time to get involved in a biotech company. I'll explain why in a moment. But first, a quick review of the phases of clinical trials... The Three Distinct Phases of Clinical Trials Before a new experimental drug is tried in humans, it's put to work in test tubes, then animals. Once it's ready for human trials, it's tested in three distinct phases. The Phase 1 trial is conducted with a limited number of subjects, usually fewer than 50. In cancer trials, the drug will be given to patients sometimes as a last resort. Drugs targeting diseases other than cancer are given to healthy volunteers so doctors can better understand how the drug reacts inside the human body. If a drug is deemed safe after this period, the company will proceed to Phase 2. This trial usually consists of a few dozen to several hundred patients receiving varying dosage levels of the particular drug. The data that's considered most accurate is from a trial that's "double blind" (neither the patient nor the doctor knows if the patient has received the drug) and placebo-controlled (compared with a placebo or standard of care). Some, but not most, Phase 2 trials are double blind and placebo-controlled. In Phase 3, companies test hundreds to thousands of patients. If the data proves that the drug is safe and effective, the company will usually apply for approval. Naturally, the more patients who take part in a trial, the greater the chance the drug fails. For example, the drug may not work, or there may be unexpected side effects. This is especially common in cancer trials, where the response rates are low, even with approved drugs. Positive results in Phase 3 can push a stock higher as investors begin focusing on approval and the sales and profits that could follow. However, it doesn't always work that way. Many drugs with seemingly strong Phase 3 results have been rejected by the FDA for one reason or another. This can crush investors who followed a drug stock all the way to the end. Alkermes (Nasdaq: ALKS) is a great example. Investors got their hopes up when Phase 2 data showed that Alkermes' antidepressant ALKS 5461 was safe and effective for patients who did not respond adequately to standard therapies... Yet the FDA rejected it after Phase 3 results, and shares tanked. This is one reason Phase 2 is the real sweet spot for biotech investing... SPONSORED [SHOCKING: $100 Billion Surging Into the 5G Market]( [Closeup $100 Bills]( What do Verizon, AT&T, T-Mobile, Dish Network, Charter Communications and Comcast have in common? According to Barron's, they're all participating in "secret bidding" to secure as much as $100 billion worth of 5G spectrum. The big winner in all of this frenzied spending? This little-known tech stock, which trades for less than $20 a share. [Get the scoop here...]( Phase 2 Trials: A Profitable Time to Be Involved in Biotech Stocks Phase 2 is often the most profitable time to be involved in a small cap biotech stock. Many times, Phase 2 results are positive. Sometimes it's because the drug works. And other times it's because the trial is rigged to provide positive results. For example, Cel-Sci (NYSE: CVM), a company that stirs passion (both positive and negative) among biotech investors, ran a Phase 2 study on the head and neck cancer drug Multikine. However, instead of being tested against existing treatments, Multikine was given along with an existing treatment. At the end of the trial, Cel-Sci boasted of a 12% complete response rate. But it was impossible to determine if the two (out of 19) patients who had a complete response saw their tumors disappear due to Multikine or the other treatment. So why would a company do that? To show good results in the hopes of raising additional capital. There are also times when the science is conducted properly and Phase 2 claims are valid, but the drug isn't able to replicate results in a Phase 3 trial. Remember, a Phase 2 trial usually contains a much smaller sample size, which can easily distort results. Very often, when a company reports strong Phase 2 results, the stock takes off, as Phase 2 results are the first real indication that the drug might be approvable. Investors get excited, potential partners begin sniffing around, and the media begins to cover the drug's potential. Even though at this point things are just starting to get promising, it's often a great time to take the money and run. Here are a few great examples... In 2019, Dermira released positive Phase 2 results for its drug lebrikizumab - an immunosuppressive used to treat asthma. Its stock doubled in value almost immediately. Novocure (Nasdaq: NVCR) - one of my past recommendations in my biotech trading research service [Lightning Trend Trader]( - released strong Phase 2 results in 2018. We closed out a 168.85% average gain over 115 days in October 2018. Something similar happened in July 2018. I recommended Regeneron Pharmaceuticals (Nasdaq: REGN) following positive Phase 2 results. Shortly thereafter, we closed out a 108% options gain. Phase 3, on the other hand, is fraught with risk. These trials are expensive to run, and there's no guarantee that the drug will again show strong results. For example, there have been some instances where the drug replicated its earlier results, but there was also a stronger-than-expected response from the placebo group, narrowing the difference that the drug made and making it appear less effective. Taking Off in Phase 2... and Failing in Phase 3 There are many examples of stocks that have taken off during or after Phase 2 results, helping investors make lots of money. But they then suffered losses when the drug failed in Phase 3. Here's a great example... Several years ago, my subscribers made money on Medivation despite a disastrous Phase 3 trial that resulted in the stock plummeting. Medivation had a drug for Alzheimer's called Dimebon. The Phase 2 results were outstanding. They showed that the drug promoted slower mental deterioration and fewer side effects than the existing therapies, including Pfizer's (NYSE: PFE) Aricept. Despite skeptics' doubts, the stock ran in anticipation of Phase 3 results. If the data was strong and the drug got approved, it would likely be an immediate blockbuster. After the stock doubled, I recommended that subscribers take half of their profits off the table. Note, this is not the usual Oxford Club philosophy. But with small cap biotech stocks that can plummet on one piece of news, I often suggest readers take their risk capital off the table once the stock has risen 100% or more. So with investors now playing with the house's money after taking their initial investment back, we waited for the Phase 3 results. As it turns out, the drug didn't work. The stock got crushed, and we sold our remaining position. But because we had sold half at a 100% profit, we still pocketed a 37% gain. Not bad for a failed drug... If the Smart Money Leaves... Take Your Profits and Follow There have been several instances where something similar has occurred. I recommended Celldex Therapeutics (Nasdaq: CLDX) right before the company released positive Phase 2 clinical trial data on its treatment for triple-negative breast cancer... and the stock surged 419%. We also made 102% gains on Delcath Systems (Nasdaq: DCTH) and 42% gains on Mela Sciences, now known as Strata Skin Sciences (Nasdaq: MELA), despite FDA rejections. Although in these cases the Phase 3 trials were not deemed a failure, the FDA rejected the applications for approval until more questions were answered. After positive Phase 2 results, you sometimes see the early investors and venture capitalists exit the position. They've made their money and don't want to stick around for the risky Phase 3. If the smart money is leaving, it may be a good idea to follow them out the door - at least with part of your investment. There's nothing wrong with hanging around to see if a small biotech company can get the ball across the goal line and get its drug approved. But considering that fewer than half of all drugs in Phase 2 actually make it to the market, it's a smart idea to take profits along the way when you can. When a solid company enters Phase 2 trials, I often see it as a powerful buy signal. But this isn't a buy-and-hold investment... You have to be ready to exit your position quickly and lock in your gains. Good investing, Marc [Leave a Comment]( JOIN THE CONVERSATION [Facebook]( [Facebook]( [Twitter]( [Twitter]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Liberty%20Through%20Wealth...&body=From%20Liberty%20Through%20Wealth:%0D%0A%0D%0APhase%202%20is%20often%20the%20most%20profitable%20time%20to%20be%20involved%20in%20a%20small%20cap%20biotech%20stock.%20Here's%20why.%0D%0A%0D [Email Share](mailto:?subject=A%20great%20piece%20from%20Liberty%20Through%20Wealth...&body=From%20Liberty%20Through%20Wealth:%0D%0A%0D%0APhase%202%20is%20often%20the%20most%20profitable%20time%20to%20be%20involved%20in%20a%20small%20cap%20biotech%20stock.%20Here's%20why.%0D%0A%0D MORE FROM LIBERTY THROUGH WEALTH [Disrupting the Disrupters]( [These Two Enterprises - Not Government - Beat COVID-19]( [Stock Market Fear... and How to Get Over It]( SPONSORED [Did This Stock-Picking Genius Uncover 2021's BIGGEST Tech Breakthrough... While Fly-Fishing in Alaska?!]( [Fly Fishing]( This financial wizard traveled to remote Alaska... meeting with ultra-wealthy CEOs and businessmen... And oddly, it was on this elite fishing trip that he first glimpsed the KEY to a coming $1 TRILLION market disruption... [Here's the true story of his remarkable discovery... and the tiny company that could soar from it.]( [The Oxford Club]( You are receiving this email because you subscribed to Liberty Through Wealth. Liberty Through Wealth is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Liberty Through Wealth]( | [Unsubscribe]( © 2021 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [1.800.589.3430](#) | International: [+1.443.353.4334](#) | Fax: [1.410.329.1923](#) [Oxfordclub.com]( The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.